Vaccination strategies in lymphomas and leukaemias: recent progress.

abstract：:The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

journal_title：Drugs

authors： Pfeiffer M,Fock RR

更新日期：1985-01-01 00:00:00

abstract：:Many drugs have a site of action within the inner ear. The list includes therapeutic, diagnostic and ototoxic agents. Therapeutic agents are most useful in cases of infections, endolymphatic hydrops, vascular insufficiency, vertigo of peripheral origin, autoimmune disease, otosclerosis (otospongiosis), sudden hearing ...

journal_title：Drugs

authors： Norris CH

更新日期：1988-12-01 00:00:00

abstract：:Available data indicate that the most common beta-lactamase produced by Branhamella catarrhalis is plasmid mediated. The same enzyme occurs in Moraxella nonliquefaciens, a commensal in the upper respiratory tract. The ability to produce the enzyme, which is known as BRO-1, can be transferred by conjugation from M. non...

journal_title：Drugs

authors： Eliasson I,Kamme C

更新日期：1986-01-01 00:00:00

abstract：:Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1...

journal_title：Drugs

authors： Schehlein EM,Robin AL

更新日期：2019-07-01 00:00:00

abstract：:A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

journal_title：Drugs

authors： Keating GM,Wellington K

更新日期：2004-01-01 00:00:00

abstract：:Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacok...

journal_title：Drugs

authors： Ceriello A,De Nigris V,Iijima H,Matsui T,Gouda M

更新日期：2019-05-01 00:00:00

abstract：:Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...

journal_title：Drugs

authors： Keating GM

更新日期：2015-07-01 00:00:00

abstract：:Approximately 70% of invasive breast cancers have some degree of dependence on the estrogen hormone for cell proliferation and growth. These tumors have estrogen and/or progesterone receptors (ER/PR+), generally referred to as hormone receptor positive (HR+) tumors, as indicated by the presence of positive staining an...

journal_title：Drugs

authors： Nunnery SE,Mayer IA

更新日期：2020-11-01 00:00:00

abstract：:Temocillin is a novel injectable beta-lactam antibiotic designed for parenteral use. It is active against the majority of Gram-negative bacteria and is stable to a wide range of beta-lactamases. Disposition and metabolic studies on temocillin in animals and man demonstrate that the drug is well distributed throughout ...

journal_title：Drugs

authors： Cockburn A,Mellows G,Jackson D,White DJ

更新日期：1985-01-01 00:00:00

abstract：:Atenolol and nifedipine have been shown to be effective single agents in angina pectoris, but reports suggest that additional benefits may be conferred by combining the 2 drugs. Therefore, to establish that the combination regimen was at least as effective as either atenolol or nifedipine alone, a multicentre study wa...

journal_title：Drugs

authors： Sandberg M,Foale RA

更新日期：1988-01-01 00:00:00

abstract：UNLABELLED:Darunavir is an oral nonpeptidic HIV-1 protease inhibitor (PI) that is used, together with a low boosting dose of ritonavir, as part of an antiretroviral therapy (ART) regimen in treatment-experienced and -naive patients with HIV-1 infection. Compared with early-generation PIs, boosted darunavir has a high g...

journal_title：Drugs

authors： McKeage K,Perry CM,Keam SJ

更新日期：2009-01-01 00:00:00

abstract：:Outpatient parenteral antibiotic therapy (OPAT) programmes are effective, well tolerated and economically advantageous in carefully selected patient populations. Inclusion criteria for patient selection for OPAT include good clinical appearance and uncomplicated infection. By virtue of their favourable microbiological...

journal_title：Drugs

authors： Esposito S

更新日期：2000-01-01 00:00:00

abstract：:The management of patients with chronic pain is a common clinical challenge. Indeed, chronic pain is often inadequately controlled in patients with cancer and in those with non-cancer chronic pain. Because of the complex nature of chronic pain, successful long-term treatment is more difficult than for acute pain. Most...

journal_title：Drugs

authors： Nicholson B

更新日期：2003-01-01 00:00:00

abstract：:The continuous-use combination oral contraceptive ethinylestradiol/levonorgestrel 20microg/90microg suppresses gonadotropins, and subsequently ovulation and endometrial thickening, and suppresses breakthrough bleeding. Amenorrhoea and absence of breakthrough bleeding increase in incidence with extended administration....

journal_title：Drugs

authors： Wagstaff AJ

更新日期：2007-01-01 00:00:00

abstract：:Lifestyle interventions constitute the initial strategy for the primary and secondary prevention of cardiovascular disease in women. However, pharmacotherapy is often indicated for control of major cardiovascular risk factors, and abundant clinical trial data support the morbidity and mortality benefit of a number of ...

journal_title：Drugs

authors： Wenger NK

更新日期：2008-01-01 00:00:00

abstract：:Azimilide is a potassium channel antagonist that, in contrast to existing class III antiarrhythmic agents, blocks both the rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current. In animal and clinical studies, azimilide prolonged repolarisation by increasing the action pot...

journal_title：Drugs

authors： Clemett D,Markham A

更新日期：2000-02-01 00:00:00

abstract：:Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2). In the EU, lapatinib in combination with capecitabine is indicated for the treatment of women with HER2-overexpressing, advanced or metas...

journal_title：Drugs

authors： Frampton JE

更新日期：2009-10-22 00:00:00

abstract：:Tipranavir is a non-peptidic HIV-1 protease inhibitor. It binds strongly and selectively, has a favourable resistance profile, and is administered orally twice daily with a subtherapeutic dosage of ritonavir in a 'boosted' regimen (TPV/r) in order to increase its bioavailability. Analysis of clinical isolates from tre...

journal_title：Drugs

authors： Croom KF,Keam SJ

更新日期：2005-01-01 00:00:00

abstract：:Significant progress has been made in the battle against transmission of HIV-1 from mother to infant. Antiretroviral regimens covering the later part of gestation, labour and the first few weeks of neonatal life have shown great efficacy in reducing such transmission. With the advent of combination antiretroviral ther...

journal_title：Drugs

authors： Kourtis AP

更新日期：2002-01-01 00:00:00

abstract：:Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab act...

journal_title：Drugs

authors： Shirley M

更新日期：2017-01-01 00:00:00

abstract：:The use of digitalis in congestive heart failure with normal sinus rhythm is still debated. While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data, with poorly documented clinical status and poor haemodynamic and exercise data, some patients did improve clinically when digitalis treatm...

journal_title：Drugs

authors： Riaz K,Forker AD

更新日期：1998-06-01 00:00:00

abstract：:The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...

journal_title：Drugs

authors： Langley MS,Heel RC

更新日期：1988-02-01 00:00:00

abstract：:Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for L-type calcium channels that has recently been approved in Japan for the treatment of patients with hypertension. Results from clinical trials showed that, in 95 patients with mild-to-moderate hypertension, long-term treatment with a...

journal_title：Drugs

authors： Wellington K,Scott LJ

更新日期：2003-01-01 00:00:00

abstract：:A number of oral and inhaled drugs are available for the long term management of patients with persistent asthma, yet the disease continues to be associated with significant morbidity and mortality. Over the past years, inhaled glucocorticoids have become established as a cornerstone of maintenance therapy because of ...

journal_title：Drugs

authors： Fabbri LM,Piattella M,Caramori G,Ciaccia A

更新日期：1996-01-01 00:00:00

abstract：:Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the Helsinki Heart Study, these effec...

journal_title：Drugs

authors： Spencer CM,Barradell LB

更新日期：1996-06-01 00:00:00

abstract：:Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

journal_title：Drugs

authors： Scott LJ

更新日期：2020-03-01 00:00:00

abstract：:Azacitidine (Vidaza) is a pyrimidine nucleoside analogue of cytidine. Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) [according to Intern...

journal_title：Drugs

authors： Keating GM

更新日期：2009-01-01 00:00:00

abstract：:Non-24-h sleep-wake disorder (non-24) is a circadian rhythm disorder occurring in 55-70% of totally blind individuals (those lacking conscious light perception) in which the 24-h biological clock (central, hypothalamic, circadian pacemaker) is no longer synchronized, or entrained, to the 24-h day. Instead, the overt r...

journal_title：Drugs

authors： Emens JS,Eastman CI

更新日期：2017-04-01 00:00:00

abstract：:Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options available to clinicians in the management of these critically ill patients. Recently, a ...

journal_title：Drugs

authors： Opal SM,Yu RL Jr

更新日期：1998-04-01 00:00:00

abstract：:The incidence of infection in clean surgery (i.e. surgery with no major contamination of the operative site) should be less than 2%, although the incidence of postoperative infections can be higher in patients with various risk factors (namely insertion of foreign bodies, a compromised immune status or prolonged durat...

journal_title：Drugs

authors： Mini E,Nobili S,Periti P

更新日期：1997-01-01 00:00:00